On this episode of BioTech Nation: how Syndax Pharmaceuticals got two new drugs approved in the last two years, for the treatment of acute myeloid leukemia and graft vs. host disease in both adults and children. CEO Michael Metzger talks to Moira about Syndax's approach to getting the drugs across the finish line, and how they've now set their sights on additional indications and cancer therapies. 

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Moira Gunn. Innehållet i podden är skapat av Moira Gunn och inte av, eller tillsammans med, Poddtoppen.